Background and Aims: RHD is characterized by haemolysis and hyperbilirubinaemia due to Rh-incompatibility. Recently, AAP guidelines recommended high-dose IVIg as an alternative to exchange transfusion (EXT). The aim of this study was to compare clinical outcome of RHD patients before and after the introduction of IVIg. Methods: A chart-review of 88 Coombs-positive RHD patients (1999-2009) was performed. Patients were divided into two groups, treated before (Group A[GA]-n°35) and after (Group B[GB]-n°53) the introduction of IVIg, respectively. Number of EXT and RBC transfusions, need and days of permanence of umbilical catheter (UC), duration of hospitalization and phototherapy; maximum bilirubinaemia, changes in bilirubinaemia over time, and morbidity were compared in the two groups. Results: GB-patients had lower EXT need (13% vs 82% in GA, p=0.000), UC need (58% vs 97%, p=0.001) and UC days (mean 2.8/patient vs 4.6, p=0.001), higher need of RBC transfusions (mean 0.9/patient vs 0.2, p=0.000), longer hospitalization (mean 12.1 days/patient vs 6.9, p=0.000) and longer phototherapy (mean 7.6 days/patient vs 4.5, p=0.000). No significant difference in maximum bilirubinaemia was found; in GB-patients bilirubinaemia overcame neurological-risk value for shorter period (mean 55.4 hours/patients vs 74.6, p=0.047). 43.9% GA-patients had thrombocytopenia, 21.9% hypocalcaemia, 4.9% hypomagnesaemia, 19.5% UC-related complications, and 9.8% adverse reactions during EXT. Two infants in GB developed NEC. Conclusions: High-dose IVIg in RHD patients reduced EXT need, UC need and permanence time, and risk of hyperbilirubinaemia-related neurological damage. However, IVIg-treated patients needed longer hospitalization, longer phototherapy, and had increased need of RBC transfusions.
High-Dose intravenous immunoglobulin (IVIG) in Rhesus Haemolytic Disease (RHD)
CORVAGLIA, LUIGI TOMMASO;ACETI, ARIANNA;FALDELLA, GIACOMO
2011
Abstract
Background and Aims: RHD is characterized by haemolysis and hyperbilirubinaemia due to Rh-incompatibility. Recently, AAP guidelines recommended high-dose IVIg as an alternative to exchange transfusion (EXT). The aim of this study was to compare clinical outcome of RHD patients before and after the introduction of IVIg. Methods: A chart-review of 88 Coombs-positive RHD patients (1999-2009) was performed. Patients were divided into two groups, treated before (Group A[GA]-n°35) and after (Group B[GB]-n°53) the introduction of IVIg, respectively. Number of EXT and RBC transfusions, need and days of permanence of umbilical catheter (UC), duration of hospitalization and phototherapy; maximum bilirubinaemia, changes in bilirubinaemia over time, and morbidity were compared in the two groups. Results: GB-patients had lower EXT need (13% vs 82% in GA, p=0.000), UC need (58% vs 97%, p=0.001) and UC days (mean 2.8/patient vs 4.6, p=0.001), higher need of RBC transfusions (mean 0.9/patient vs 0.2, p=0.000), longer hospitalization (mean 12.1 days/patient vs 6.9, p=0.000) and longer phototherapy (mean 7.6 days/patient vs 4.5, p=0.000). No significant difference in maximum bilirubinaemia was found; in GB-patients bilirubinaemia overcame neurological-risk value for shorter period (mean 55.4 hours/patients vs 74.6, p=0.047). 43.9% GA-patients had thrombocytopenia, 21.9% hypocalcaemia, 4.9% hypomagnesaemia, 19.5% UC-related complications, and 9.8% adverse reactions during EXT. Two infants in GB developed NEC. Conclusions: High-dose IVIg in RHD patients reduced EXT need, UC need and permanence time, and risk of hyperbilirubinaemia-related neurological damage. However, IVIg-treated patients needed longer hospitalization, longer phototherapy, and had increased need of RBC transfusions.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.